Close Menu

DigiLab

The National Institutes of Health has awarded a team of Harvard University researchers nearly $300,000 to develop a new microarray platform capable of imaging millions of bacterial cells in an overnight experiment.

Under the terms of the deal, Holliston, Mass.-based Digilab will sell Axela's Ziplex system for gene and protein expression analysis and dotLab mX system for real-time immunoassays.

The deal calls for Digilab to market new versions of Axela's proprietary flow-through technologies, the Ziplex system and the dotLab mX system.

Nearly four years after it acquired Harvard Bioscience's Genomic Solutions business, DigiLab is looking to parlay those microarray assets into the market for live cell arrays, and the stem cell research market in particular.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.